You are here:Home-Inhibitors & Agonists-JAK/STAT Signaling-JAK

Request The Product List ofJAK JAK

Cat. No. Product Name CAS No. Information

AZD 4205


AZD 4205 (AZD4205) is a potent, selective JAK1 inhibitor IC50 of 73 nM and Ki of 2.8 nM, shows high selectivity against JAK2 and JAK3 with IC50 of 13,233 nM and >30,000 nM respectively; shows potent inhibition of p-STAT3 in a cell based assay of JAK1 activity with an IC50 of 128 nM and excellent selectivity across the kinome; reduces residual disease and prolongs the benefit of Osimertinib in lung cancer patients with EGFR activating mutations both in vitro and in vivo.

Lung Cancer

Phase 2 Clinical


AS 2553627


AS 2553627 (AS2553627) is a novel potent, selective pan-JAK inhibitor with IC50 of 0.46, 0.30, 0.14 and 2.0 nM for JAK1, JAK2, JAK3 and TYK2, respectively; displays no inhibitory activity against a panel of protein kinases, including SYK and ZAP70 at 1 uM; inhibits proliferation of IL-2 stimulated human and rat T cells with IC50 of 2.4 and 4.3 nM, respectively, inhibits the proliferation of TF-1 cells stimulated with EPO with IC50 of 12 nM; effectively prevents chronic rejection in rat cardiac allografts in rat cardiac transplant model alone or co-administration with tacrolimus.




PF-04965842(PF04965842) is a potent, selective, orally bioavailable JAK1 inhibitor with IC50 of 29 nM; exhibits good selective inhibition profile for JAK1 versus other JAK family enzymes (IC50=803/>10,000/1250 nM for JAK2/JAK3/TYK2, respectively); demonstrates efficacy in a rat adjuvant-induced arthritis (rAIA) model.


Phase 3 Clinical



Delgocitinib (JTE-052, LEO 124249) is a potent, selective, orally active, pan-JAK inhibitor with IC50 of 2.8, 2.6, 13 and 58 nM for JAK1,2,3 and Tyk2, respectively; does not inhibit a broad panel of kinases with exception of ROCK-II (IC50=140 nM); inhibits cytokine signaling evoked by IL-2, IL-6, IL-23, granulocyte/macrophage CSF, and IFN-α in vitro; potently suppresses the IL-2-induced IFN-γ production in mice (ED50=1.1 mg/kg), suppresses inflammatory responses in collagen-induced arthritis model.
Phase 2 Clinical



PF-06263276 (PF06263276, PF 6263276) is a potent, selective pan JAK inhibitor with IC50 of 2.2, 23.1, 59.9 and 29.7 nM for JAK1, JAK2, JAK3, and TYK2, respectively; demonstrates good JAK potency and kinase selectivity, exhibts inhibitory potency in human whole blood versus various stimulatory cytokines (IFNα, IL-23, IL-4, IL-6 and GM-CSF) with IC50 of 0.6-5.2 uM; suitable for inhaled and topical delivery in vivo.


Phase 1 Discontinued




Upadacitinib (ABT-494) is a potent and selective JAK1 inhibitor with celluar IC50 of 8 nM, biochemical IC50 of 40 nM; displays 74-fold and 50-fold selectivity over JAK2 and JAK3, respectively; a second-generation JAK inhibitor in development for rheumatoid arthritis.

Rheumatoid Arthritis

Phase 3 Clinical




Peficitinib (ASP-015K, JNJ-54781532) is a potent JAK inhibitor with IC50s of 3.9 and 0.7 nM for JAK1 and JAK3 respectively; inhibits IL-2-dependent T cell proliferation in vitro and STAT5 phosphorylation in vitro and ex vivo; dose-dependently suppresses bone destruction and paw swelling in an adjuvant-induced arthritis model in rats; orally bioactive.

Rheumatoid Arthritis

Phase 3 Clinical

Request The Product List

* Indicates a Required FieldYour information is safe with us.

  • *Product List:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Country:
  • Additional Information:
Contact Us